Optimizing Treatment Outcomes - National Multiple Sclerosis Society

Skip to navigation Skip to content

Optimizing Treatment Outcomes

Share

In this article

Factors

Optimizing treatment outcomes with disease-modifying therapies involves several factors:

Initiating the appropriate treatment at the appropriate time.

  • Most MS specialists advocate for early intervention, although differences of opinion exist within the MS community:
  • The following image of the natural history of MS indicates the significant amount of MRI activity that occurs in the pre-clinical phase and early relapsing-remitting MS, the gradual decrease in inflammatory attacks (relapses) over time, and the increasing MRI burden of disease that occurs along with a decrease in brain volume. This schematic supports the role of DMTs early in the disease course.

CMS_ms.natural.history (.png)


Consensus criteria

Consensus Criteria for Sub-Optimal Response (Cohen et al., 2004)

  • No relapse rate reduction or > 1 relapse/year after 6-12 months of continuous DMT
  • Recurrent or new spinal cord or brainstem lesions
  • Incomplete recovery from repeated relapses, especially when EDSS (.pdf) score increases
  • Progressive cognitive or motor impairment that disrupts ADLs regardless of neurological exam changes (eliminating the influence of medications, depression, or superimposed concurrent illness)
  • Polyregional disease development that affects multiple neurologic systems

Share

Diagnosis & Management Healthcare Professional App

Download this unique, FREE tool and resource that provides important information about the diagnosis and management of multiple sclerosis for practicing clinicians. The App is a concise compilation of current, easy-to-reference, evidence-based information that you can access at no charge as an Apple, Droid and Windows "App".

App production made possible by Allergan, Bayer HealthCare, Novartis and Questcor Pharmaceuticals, Inc.

Download for iPhone

Download for Android

Download for Windows Phone